Shots:
- Chiesi Group has entered into an exclusive license deal with Aliada Therapeutics, an AbbVie subsidiary, to advance its Blood-Brain Barrier (BBB)-crossing platform technology for developing therapies targeting lysosomal storage disorders
- As per the deal, Chiesi will receive an exclusive global license to develop & commercialize enzyme replacement therapies using its BBB-crossing platform, with Aliada receiving upfront, development & sale-based milestones, plus tiered royalty payments, while Chiesi will fund all R&D & commercialization
- Deal builds on a 2023 collaboration for enzyme cargoes modified with Aliada’s MODEL platform, which leverages brain endothelial transport mechanisms to deliver large molecules across the BBB
Ref: Chiesi | Image: Chiesi & Aliada Therapeutics| Press Release
Related News:- EirGenix Enters ~$152M Licensing Deal with Sandoz to Commercialize EG1206A (Biosimilar, Perjeta)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
